Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)

Trial Profile

A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2019

At a glance

  • Drugs Sarilumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms RA-EXTEND; SARIL-RA-EXTEND
  • Sponsors Sanofi; Sanofi Genzyme
  • Most Recent Events

    • 15 Jul 2019 Results (n=2887) of post-hoc pooled analysis of eight studies (MOBILITY, NCT01061736; TARGET, NCT01709578; ASCERTAIN, NCT01768572; MONARCH, NCT02332590; ACT11575, NCT01217814; ONE, NCT02121210; COMPARE, NCT01764997; and EASY, NCT02057250) and one open label extension (EXTEND; NCT01146652) assessing long-term safety up to 7 years follow up of sarilumab in rheumatoid arthritis patients, published in the Rheumatology.
    • 15 Jun 2019 Results assessing long-term safety from the sarilumab clinical development program from MOBILITY (NCT01061736), TARGET (NCT01709578), ASCERTAIN (NCT01768572), EASY (NCT02057250), COMPARE (NCT01764997), ACT11575 (NCT01217814), MONARCH (NCT02332590), ONE (NCT02121210), and the open-label extension EXTEND (NCT01146652) trials presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Jun 2019 Safety and efficacy results presented at the 20th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top